Details
Historically, ATTR-CM was considered a rare disease; however, it is now recognized as a more common cause of heart failure (HF) than previously thought. Despite recent attention to ATTR-CM, the condition is significantly underdiagnosed. Timely diagnosis is crucial, as it has the potential to reduce mortality and HF hospitalization when treated with targeted therapies. In this symposium, ATTRCM experts (symposium chair Dr. Mathew Maurer, faculty members Dr. Jan Griffin and Dr. Frederick Ruberg), will provide attendees with best practices for evaluating, diagnosing, and treating patients with ATTR-CM.
Educational Objectives:
- Recognize the cardiac and extracardiac red flags which raise suspicion for ATTR-CM.
- Describe the diagnostic testing components to quickly and accurately diagnose ATTR-CM.
- Summarize current recommendations for use of HF GDMT in ATTR-CM patients and the evolving evidence for Silencers and Stabilizers for ATTR-CM.
- Identify the recommended parameters for monitoring disease progression in ATTR-CM.